Stockreport

Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD

Albireo Pharma, Inc.  (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
PDF On track to report topline data mid-2020 BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disea [Read more]